The national burden of avoidable EPRDs in adults â„16 years in Scotland was quantified. The study had a retrospective, sequential cross-sectional design. The 2016 Office for National Statisticsâ Revised Definition of Avoidable Mortality Causes was used to identify potentially avoidable EPRDs.
International Classification of Disease (ICD-10) G40-41-coded causes of death had the highest positive predictive values for epilepsy diagnosis, at 93%. G40-41 captured 2,149 EPRDs, 1,276 (59%) of which had â„1 seizure-/epilepsy-related hospital admission during 2009â2016. However, only 516 (24%) of these patients visited a neurology clinic during this period. Mortality rates per 100,000 ranged between 6.8 (95% CI 6.0â7.6) in 2009 and 9.1 (95% CI 8.2â9.9) in 2015. Standardised mortality ratios were higher in adults â€55 years, peaking at 6.0 (95% CI 2.3â9.7) between ages 16-24 years. Of young adult EPRDs, 78% were deemed potentially avoidable. The most common mechanisms of death were sudden unexpected death in epilepsy, aspiration pneumonia, cardiac arrest, alcohol use, and congenital malformation.
- Mbizvo G, et al. Abstract O3007, EAN 2020.
Posted on
Previous Article
« How genetic testing can contribute to epilepsy management Next Article
Directional DBS superior to omnidirectional DBS »
« How genetic testing can contribute to epilepsy management Next Article
Directional DBS superior to omnidirectional DBS »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
White matter matters in Parkinsonâs disease

September 10, 2020
Long-term safety of satralizumab consistent with double-blind periods
September 9, 2020
Sleep disorders mark PD progression
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com